PMID- 30541952
OWN - NLM
STAT- MEDLINE
DCOM- 20190129
LR  - 20200225
IS  - 0973-7138 (Electronic)
IS  - 0250-5991 (Linking)
VI  - 43
IP  - 5
DP  - 2018 Dec
TI  - Primary study on the hypoglycemic mechanism of 5rolGLP-HV in STZ-induced type 2 
      diabetes mellitus mice.
PG  - 921-929
AB  - 5rolGLP-HV is a promising dual-function peptide for the treatment of diabetes and 
      thrombosis simultaneously. For investigating the therapeutic mechanism of 
      5rolGLP-HV for type 2 diabetes mellitus (T2DM), STZ-induced diabetic mice were 
      established and treated with 5rolGLP-HV. The results showed that daily water and 
      food intake, blood glucose, serum and pancreatic insulin levels significantly 
      decreased after 5rolGLP-HV treatment with various oral concentrations, and 16 
      mg/kg was the optimal dose for controlling diabetes. 5rolGLP-HV treatment 
      decreased the MDA levels and the T-SOD activity in serum and pancreatic of 
      diabetic mice (but not up to significant difference), and significantly increased 
      the expression of signal pathways related genes of rolGLP-1, also the density of 
      insulin expression and the numbers of apoptosis cells in islets of diabetic mice 
      were significantly decreased in comparison to the negative diabetic mice. These 
      effects above may be clarified the hypoglycemic mechanisms of 5rolGLP-HV, and 
      5rolGLP-HV may be as a potential drug for diabetes in future.
FAU - Wang, Yanan
AU  - Wang Y
AD  - Lianyungang Maternal and Children's Health Hospital, Lianyungang 222001, Jiangsu, 
      China.
FAU - Li, Minggang
AU  - Li M
FAU - Ni, Zaizhong
AU  - Ni Z
LA  - eng
PT  - Journal Article
PL  - India
TA  - J Biosci
JT  - Journal of biosciences
JID - 8100809
RN  - 0 (Blood Glucose)
RN  - 0 (Glp1r protein, mouse)
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Hirudins)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (Recombinant Proteins)
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - 5W494URQ81 (Streptozocin)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
RN  - EC 1.15.1.1 (Superoxide Dismutase)
RN  - EC 2.7.1.- (Phosphatidylinositol 3-Kinases)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 2.7.11.11 (Cyclic AMP-Dependent Protein Kinases)
RN  - EC 2.7.11.25 (MAP Kinase Kinase Kinases)
SB  - IM
MH  - Animals
MH  - Blood Glucose/drug effects/metabolism
MH  - Cyclic AMP-Dependent Protein Kinases/genetics/metabolism
MH  - Diabetes Mellitus, Experimental/chemically induced/*drug 
      therapy/genetics/metabolism
MH  - Drinking/drug effects
MH  - Drug Evaluation, Preclinical
MH  - Eating/drug effects
MH  - Gene Expression Regulation
MH  - Glucagon-Like Peptide 1/biosynthesis/*pharmacology
MH  - Glucagon-Like Peptide-1 Receptor/genetics/metabolism
MH  - Hirudins/chemistry
MH  - Hypoglycemic Agents/metabolism/*pharmacology
MH  - Insulin/*blood
MH  - Islets of Langerhans/drug effects/metabolism/pathology
MH  - MAP Kinase Kinase Kinases/genetics/metabolism
MH  - Male
MH  - Malondialdehyde/antagonists & inhibitors/metabolism
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Phosphatidylinositol 3-Kinases/genetics/metabolism
MH  - Proto-Oncogene Proteins c-akt/genetics/metabolism
MH  - Recombinant Proteins/biosynthesis/*pharmacology
MH  - Streptozocin
MH  - Superoxide Dismutase/metabolism
EDAT- 2018/12/14 06:00
MHDA- 2019/01/30 06:00
CRDT- 2018/12/14 06:00
PHST- 2018/12/14 06:00 [entrez]
PHST- 2018/12/14 06:00 [pubmed]
PHST- 2019/01/30 06:00 [medline]
PST - ppublish
SO  - J Biosci. 2018 Dec;43(5):921-929.